問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
陳健弘
下載
2021-01-01 - 2026-12-31
Condition/Disease
Test Drug
Participate Sites3Sites
Recruiting3Sites
2020-03-01 - 2028-12-31
Participate Sites8Sites
Recruiting8Sites
2019-03-01 - 2024-12-26
Participate Sites9Sites
Recruiting9Sites
2019-11-01 - 2025-02-28
2020-06-01 - 2026-12-31
Participate Sites4Sites
Recruiting4Sites
2017-01-01 - 2028-12-31
Participate Sites6Sites
Recruiting6Sites
2019-11-30 - 2026-09-30
2019-12-20 - 2024-08-16
advanced hepatocellular carcinoma (HCC)
1. Regorafenib (BAY-73-4506) 2. Tislelizumab (BGB-A317)
Participate Sites2Sites
Recruiting2Sites
2018-09-01 - 2022-12-31
Hepatocellular Carcinoma (HCC)
nivolumab﹝Opdivo﹞/ ipilimumab ﹝Yervoy﹞
2018-03-01 - 2021-01-04
Previously Treated Unresectable Hepatocellular Carcinoma
BGB-A317
Recruiting5Sites
Terminated1Sites
Division of General Internal Medicine
Division of Hematology & Oncology
全部
